These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34718044)

  • 21. Nasal route favors the induction of CD4
    Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
    Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.
    Li L; Barry V; Daffis S; Niu C; Huntzicker E; French DM; Mikaelian I; Lanford RE; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):912-921. PubMed ID: 29247724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
    Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
    Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
    Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
    Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response.
    Petit MA; Capel F; Zoulim F; Dubanchet S; Chemin I; Penna A; Ferrari C; Trépo C
    Arch Virol Suppl; 1992; 4():105-12. PubMed ID: 1280500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
    Martin P; Dubois C; Jacquier E; Dion S; Mancini-Bourgine M; Godon O; Kratzer R; Lelu-Santolaria K; Evlachev A; Meritet JF; Schlesinger Y; Villeval D; Strub JM; Van Dorsselaer A; Marchand JB; Geist M; Brandely R; Findeli A; Boukhebza H; Menguy T; Silvestre N; Michel ML; Inchauspé G
    Gut; 2015 Dec; 64(12):1961-71. PubMed ID: 25429051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients.
    Vyas AK; Sharma BC; Sarin SK; Trehanpati N
    Liver Int; 2018 Jan; 38(1):38-49. PubMed ID: 28500636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection.
    Du DW; Jia ZS; Li GY; Zhou YY
    World J Gastroenterol; 2003 Jan; 9(1):108-11. PubMed ID: 12508362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation.
    Schubert A; Michel D; Mertens T
    BMC Infect Dis; 2013 May; 13():223. PubMed ID: 23679074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure.
    Wong GL; Wong VW; Yuen BW; Tse YK; Yip TC; Luk HW; Lui GC; Chan HL
    J Hepatol; 2020 Jan; 72(1):57-66. PubMed ID: 31499132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication.
    Hu Z; Hu J; Ren F; Xu H; Tan M; Wang Q; Ren J
    Biochem Biophys Res Commun; 2020 Mar; 523(3):802-808. PubMed ID: 31954513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fusion protein of tapasin and hepatitis B core antigen 18‑27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice.
    Tang Y; Chen X; Zhang Y; Tang Z; Zhuo M; Li D; Wang P; Zang G; Yu Y
    Mol Med Rep; 2014 Apr; 9(4):1171-8. PubMed ID: 24535102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant.
    Xue Y; Wang MJ; Yang ZT; Yu DM; Han Y; Huang D; Zhang DH; Zhang XX
    Emerg Microbes Infect; 2017 Mar; 6(3):e15. PubMed ID: 28325923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
    Agarwal K; Ahn SH; Elkhashab M; Lau AH; Gaggar A; Bulusu A; Tian X; Cathcart AL; Woo J; Subramanian GM; Andreone P; Kim HJ; Chuang WL; Nguyen MH
    J Viral Hepat; 2018 Nov; 25(11):1331-1340. PubMed ID: 29851204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Characteristics of lymphocyte phenotypes in HBV transgenic mice and the effect of interferon-α: a preliminary study].
    Yan X; Zhong RH; Liu JH; Zhou Y; Tang LB; Li YY; Liu GZ; Hou JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):870-4. PubMed ID: 27320894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo.
    Furukawa S; Akbar SM; Hasebe A; Horiike N; Onji M
    Immunobiology; 2004; 209(7):551-7. PubMed ID: 15568619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.